脑瘤药物市场（按产品类型、治疗方法、肿瘤类型、最终用户和分销管道划分）—2025-2032 年全球预测

预计到 2032 年脑癌药物市场规模将成长至 62.9 亿美元，复合年增长率为 8.49%。

主要市场统计数据
基准年2024年	32.8亿美元
预计2025年	35.6亿美元
预测年份：2032年	62.9亿美元
复合年增长率（%）	8.49%

为决策者提供现代脑肿瘤治疗环境框架，整合临床创新、照护途径和商业化槓桿

脑肿瘤治疗处于快速科学创新与持久临床复杂性的交会点，需要高阶主管能够整合技术、临床实务和商业策略。分子诊断和精准医疗的最新进展正在改变患者的治疗路径，拓展可用的干预措施范围，同时也提升了跨专业团队协调治疗的重要性。同时，影像和外科技术的创新正在改变手术全期决策，为设备和服务供应商创造新的机会，使其能够提升显着的价值。

本报告的引言重点概括了影响原发性脑肿瘤治疗方案的临床、监管和商业性动态。它概述了常见的治疗方法、辅助设备的作用，以及最终用户（包括医院、专科诊所和门诊手术中心）如何调整治疗途径。报告自始至终强调了循证应用的驱动因素、报销和可及性考量，以及对开发设备和药物疗法的公司的战略意义。其目标是帮助决策者简洁地了解问题陈述、商业化的关键槓桿，以及哪些领域的额外投资和合作可以带来可衡量的临床和经济效益。

精准诊断、适应性证据产生和以价值为中心的护理模式如何重塑治疗开发和商业性执行

脑肿瘤治疗领域正在经历变革性变化，这正在重新定义临床决策和商业性重点。精准肿瘤学的进展，例如分子分型和标靶免疫治疗，正在将异质性疾病类别转化为更具可操作性的治疗队列，从而影响试验设计、监管策略和市场准入顺序。与药理学进展同步，影像和放射治疗技术也在不断发展，从而提高了精准度并减轻了附带损害，迫使临床团队重新思考治疗顺序和联合策略。

同时，数位健康、真实世界证据和自适应临床试验框架的整合正在加速迭代学习，缩短从概念验证到广泛临床应用的时间。支付者和医疗系统越来越关注基于价值的指标，要求製造商不仅要证明疗效，还要证明长期患者疗效和成本效益。因此，能够将科学差异化与现实部署路径（例如优化的分销管道和医院整合模式）相结合的公司将获得巨大的临床和商业性利益。这种转变迫使製造商和供应商重新思考伙伴关係、证据产生和上市路径，以保持竞争力。

评估近期关税变化如何改变治疗和医疗设备的供应链弹性、采购动态和商业性成本结构

贸易政策和关税趋势可能会为整个治疗方法的製造商和经销商带来重大的成本和供应链考量。 2025年，美国关税的变化对进口医疗设备和某些药品投入产生了累积影响，促使製造商重新评估筹资策略和成本结构。对于器械製造商而言，依赖全球化供应链的组件（例如影像感测器和放射治疗系统组件）的投入成本上涨，导致其重新评估与医院系统和经销商的采购谈判。

当原料药和特殊包装从国际采购时，製药商面临间接成本压力，这迫使他们重新谈判合同，在某些情况下甚至需要部分回流或实现供应商多元化。这些调整强化了供应链透明度和与最终用户签订合约弹性的重要性。医疗保健提供者和付款人对此的回应是要求提供更有力的医疗总成本证据，并延长保固期和服务承诺，以降低成本波动性。展望未来，积极将关税相关成本纳入定价、管理采购和临床价值提案的相关人员将更有能力在保持利润率的同时，保持净利率的可及性和应用性。

分析医疗设备、药品和临床路径的需求驱动因素，以确定差异化的采用模式和商业化途径

它确定了临床需求和机会的交汇点，包括产品类型、治疗方法、肿瘤类型、最终用户和分销管道。依产品类型，市场分为医疗设备和药品。医疗设备包括诊断影像设备、放射设备和手术器械。化疗包括烷化剂、抗代谢物和植物碱。免疫疗法包括CAR-T疗法、查核点抑制剂和疫苗。放射线治疗包括近距离放射治疗、体外放射线治疗和立体定位放射线手术。

不同类型的肿瘤（星状细胞瘤、胶质母细胞瘤、脑膜瘤）表现出不同的临床疗效和治疗强度，这会影响产品选择和服务利用。最终用户（例如门诊手术中心、医院和专科诊所）拥有不同的资本预算、病例组合和转诊网络，这些因素决定了采购时间表和商业性参与策略。分销管道（例如医院药房、线上药房和零售药房）影响患者的用药管道、依从性支援和管道经济效益。综上所述，这些细分市场表明，根据特定的产品、治疗方法、肿瘤类型和医疗环境组合，量身定制临床证据、定价模型和上市后服务，对于加速药物应用和确立商业性定位至关重要。

发现区域监管和付款人的异质性，以协调证据生成、市场进入顺序和区域商业化策略，实现全球扩张

区域动态决定了不同的监管、报销和临床应用环境，因此需要製定针对特定区域的市场策略。在美洲，领先的学术中心和综合医疗系统通常会推动高成本疗法和复杂医疗设备的早期采用，而私人付款人和捆绑支付模式则决定了医疗服务的取得和报销途径。在欧洲、中东和非洲，监管的多样性和不同的报销门槛，再加上集中核准和分散的卫生技术评估并存，需要灵活的证据基础和针对特定区域的经济模式。亚太地区在医疗保健现代化方面呈现不同的轨迹。在某些市场，医院的快速扩张和对肿瘤中心的投资正在创造对高性能医疗设备和新型疗法的巨大需求，而在其他市场，则强调成本控制和本地製造合作伙伴关係。

这些区域差异会影响临床试验地点的选择、市场进入时机以及患者可近性计画的设计。因此，製造商必须调整其监管策略、本地证据产生和经销伙伴关係，以符合区域付款人的期望和供应商的能力。此外，与关键意见领袖和区域临床网络的合作对于将全球证据转化为本地相关的实践变革并加快本地报销谈判至关重要。

创新者、设备製造商和经销商的产品和服务整合策略如何重新定义竞争优势和伙伴关係模式

脑肿瘤治疗生态系统的关键参与者在互补领域开展业务，包括创新药物开发商、设备製造商、服务供应商和专业分销商，各自构成复杂的价值链。製药创新者越来越多地将分子标靶疗法和免疫疗法与伴随诊断相结合，从而增强了生物标记主导的患者选择在临床和商业性成功中的作用。医疗设备製造商正在透过结合成像、导航和治疗交付的整合解决方案实现差异化，以简化手术工作流程并改善临床结果。

服务供应商和委外研发机构正在扩展其服务范围，以支援自适应试验设计、真实世界证据平台和健康经济模型，使申办方能够更快地证明其价值提案。分销商和专业药房正在加强患者援助计划和专业物流，以满足重症患者的需求。在整个生态系统中，共同开发、授权或综合服务协议等策略联盟正成为降低创新风险、加速临床试验和上市时间的首选方式。能够展示综合解决方案、可扩展支持模式和强大临床证据的组织将在临床应用和长期商业性永续性方面处于领先地位。

高阶主管应优先采取的策略性措施是同步证据产生、供应弹性和灵活的商业化，以加速采用

行业领导者应优先考虑一系列切实可行的倡议，将科学差异化与现实的商业性执行和付款人期望相结合。首先，投资于有针对性的证据生成，将临床终点与健康经济结果相结合，使付款人和医疗系统能够评估长期价值和短期有效性。其次，透过多元化采购、确保关键零件的冗余性以及将关税和贸易敏感性分析纳入定价模型来优化供应链弹性，以保护利润率和医疗服务的连续性。第三，发展灵活的商业模式，以反映最终用户的多样性。医院、门诊手术中心和专科诊所各自需要不同的收购、资金筹措和服务结构。

此外，儘早与当地监管和报销相关人员沟通，确保满足当地证据要求，并考虑采用适应性试验设计和实用性研究，以加速现实世界的推广应用。建立策略联盟，将设备和疗法与数位工具和病患支援服务结合，打造捆绑式价值提案。最后，优先进行临床医师和病患教育项目，以阐明治疗顺序、联合治疗原理和预期疗效，从而铺平从监管核准到纳入标准治疗的整个过程。这些行动结合起来，可以减少推广障碍，增强商业性韧性。

将临床、商业和政策情报与专家访谈和比较案例分析相结合的透明混合方法可确保获得切实可行的见解

本分析所依据的调查方法稳健有效，透过系统性文献综述、与领域专家进行初步定性访谈以及对二手资料来源的三角检验，得以验证。初步访谈对象包括临床医生、医院采购负责人、设备工程师、付款方和商务主管，旨在了解跨职能观点对临床效用、采购偏好和市场进入条件的看法。二级资讯来源包括同侪审查的临床文献、监管备案文件、指南更新和公共公告，旨在为检验证据和当前实践模式提供深入见解。

资料整合利用主题分析来识别反覆出现的采用驱动因素、障碍和区域差异，而比较案例研究突显了商业化成功案例和伙伴关係关係典范。在适当的情况下，我们进行了敏感性检验，以检验关于供应链动态和医疗保健提供者购买行为的假设。本调查方法强调资讯来源归因和分析假设的透明度，旨在为策略规划、伙伴关係评估和证据产生优先排序提供可靠且可操作的见解。

整合临床创新、商业性严谨性和本地细微差别，以确定将治疗进步转化为持久影响的策略槓桿

总而言之，脑肿瘤治疗领域的特点是科学进步迅速、治疗途径不断发展以及商业性动态复杂，需要涵盖证据生成、供应链设计和市场准入的整合策略。精准诊断和新型免疫疗法正在提高临床差异化的标准，而影像、放射和外科技术的进步正在重塑实践模式。同时，关税和贸易变化暴露了供应链的脆弱性，需要积极主动的管理来维持可及性和财务绩效。监管和报销方面的区域差异进一步凸显了製定本地策略和伙伴关係关係的必要性。

综上所述，能够将可靠的临床证据与实用的商业模式、灵活的采购惯例以及有针对性的本地参与相结合的组织，将最有能力将创新转化为持续的临床和商业性影响力。未来的道路是强调产业、相关人员和付款相关人员之间的合作，以及严谨的证据和价值展示方法，以满足医疗服务提供者和病患的需求。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 针对肿瘤特异性抗原的个人化疫苗疗法的应用日益广泛
• 免疫疗法与标靶药物结合的多模态治疗方法的出现
• 基于血液的液态生物检体检测在早期检测脑肿瘤復发的进展
• 增加对侵袭性和復发性胶质母细胞瘤 CAR-T 细胞疗法的投资
• 整合人工智慧影像分析，改善肿瘤分割和治疗计划
• 治疗瀰漫性内源性脑桥胶质瘤的血脑障壁渗透性小分子化合物的开发
• 患者报告的结果对于指导神经认知保留治疗策略的重要性日益增加
• 生物技术先驱与学术机构进行策略合作，共同发现新的胶质瘤标靶
• 监管部门的核准加速了高级别胶质瘤溶瘤病毒疗法的普及
• 投资自适应临床试验设计加速脑肿瘤治疗评估

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章脑瘤药物市场（依产品类型）

• 装置
  • 影像设备
  • 辐射设备
  • 手术器械
• 製药

第九章脑肿瘤药物市场（依治疗方法）

• 化疗
  • 烷化剂
  • 抗代谢物
  • 植物生物碱
• 免疫疗法
  • CAR T
  • 查核点抑制剂
  • 疫苗
• 放射线治疗
  • 近距离放射治疗
  • 体外放射治疗
  • 立体定位放射线手术
• 外科手术
  • 开颅手术
  • 立体定位手术

第 10 章脑肿瘤药物市场（依肿瘤类型）

• 星状细胞瘤
• 神经胶母细胞瘤
• 脑膜瘤

第 11 章脑肿瘤药物市场（依最终使用者）

• 门诊手术中心
• 医院
• 专科诊所

第十二章脑肿瘤药物市场（依通路）

• 医院药房
• 网路药局
• 零售药局

第十三章脑瘤药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章脑肿瘤药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 脑瘤药物市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novocure Ltd.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • AbbVie Inc.
  • AstraZeneca plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc

The Brain Tumor Therapeutics Market is projected to grow by USD 6.29 billion at a CAGR of 8.49% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 3.28 billion
Estimated Year [2025]	USD 3.56 billion
Forecast Year [2032]	USD 6.29 billion
CAGR (%)	8.49%

Framing the contemporary brain tumor therapeutic environment by integrating clinical innovation, care pathways, and commercialization levers for decision-makers

Brain tumor therapeutics sit at the intersection of rapid scientific innovation and enduring clinical complexity, requiring an executive lens that integrates technology, clinical practice, and commercial strategy. Recent advances in molecular diagnostics and precision therapeutics have altered patient pathways, expanding the range of interventions available while also increasing the importance of coordinated care across multidisciplinary teams. At the same time, procedural innovations in imaging and surgical techniques have changed perioperative decision making, creating new opportunities for device and service providers to add demonstrable value.

This introduction positions the report as a focused synthesis of clinical, regulatory, and commercial dynamics shaping therapeutic choices for primary brain tumors. It outlines the prevailing therapeutic approaches, the role of complementary devices, and how end users such as hospitals, specialty clinics, and ambulatory surgical centers are adapting care pathways. Throughout, emphasis is placed on evidence-based adoption drivers, reimbursement and access considerations, and the strategic implications for companies developing devices or pharmacologic therapies. The aim is to equip decision-makers with a concise framing of the problem set, the levers that matter in commercialization, and the domains where additional investment or collaboration can yield measurable clinical and economic returns.

How precision diagnostics, adaptive evidence generation, and value-focused care models are reshaping therapeutic development and commercial execution

The landscape for brain tumor therapeutics is undergoing transformative shifts that are redefining clinical decision-making and commercial priorities. Precision oncology advances, such as molecular subtyping and targeted immunotherapies, have converted heterogeneous disease categories into more actionable treatment cohorts, thereby influencing trial design, regulatory strategy, and market entry sequencing. Parallel to pharmacologic progress, imaging and radiation technologies have evolved to provide greater precision and reduced collateral damage, prompting clinical teams to reassess treatment sequencing and combination strategies.

Concurrently, the convergence of digital health, real-world evidence, and adaptive clinical trial frameworks has accelerated iterative learning, shortening the time between proof-of-concept and broader clinical adoption. Payers and health systems are increasingly focused on value-based metrics, pushing manufacturers to demonstrate not only efficacy but also longitudinal patient outcomes and cost-effectiveness. As a result, organizations that can align scientific differentiation with pragmatic deployment pathways-such as optimized distribution channels and hospital integration models-will capture disproportionate clinical and commercial upside. These shifts compel manufacturers and providers to rethink partnerships, evidence generation, and market access pathways in order to remain competitive.

Assessing how recent tariff developments have altered supply chain resilience, procurement dynamics, and commercial cost structures in therapeutics and devices

Trade policy and tariff dynamics can introduce material cost and supply chain considerations for manufacturers and distributors across therapeutic modalities. In 2025, tariff changes in the United States have had a cumulative effect on imported devices and certain pharmaceutical inputs, prompting manufacturers to reassess sourcing strategies and cost structures. For device makers, components that rely on globalized supply chains, including imaging sensors or radiation delivery system parts, experienced input-cost inflation that translated to revised procurement discussions with hospital systems and distributors.

Pharmaceutical manufacturers faced indirect cost pressure where APIs and specialty packaging were sourced internationally, requiring contract renegotiations and, in some instances, partial reshoring or diversification of suppliers. These adjustments increase the importance of supply chain transparency and contractual flexibility with end users. Providers and payers responded by seeking stronger total-cost-of-care evidence and longer-term warranties or service commitments to mitigate variability. Moving forward, stakeholders that proactively model tariff-related expenses into pricing, managed procurement, and clinical value propositions will be better positioned to sustain margins while preserving access and adoption.

Dissecting demand drivers across devices versus pharmaceuticals and clinical pathways to reveal differentiated adoption patterns and commercialization levers

Key segmentation insights reveal where clinical demand and commercial opportunity intersect across product type, therapeutic approach, tumor type, end user, and distribution channels. When analyzed by product type, the market divides into devices and pharmaceutical offerings, with devices themselves comprising imaging equipment, radiation equipment, and surgical instruments; this division highlights different adoption cycles, capital expenditure profiles, and service model requirements for providers. Therapeutic approach further stratifies demand across chemotherapy, immunotherapy, radiotherapy, and surgery; chemotherapy includes alkylating agents, antimetabolites, and plant alkaloids, while immunotherapy encompasses CAR T therapies, checkpoint inhibitors, and vaccines, and radiotherapy spans brachytherapy, external beam radiotherapy, and stereotactic radiosurgery, whereas surgical approaches range from craniotomy to stereotactic surgery, each pathway implicating distinct clinical workflows and evidence needs.

Tumor type segmentation-astrocytoma, glioblastoma, and meningioma-illustrates heterogeneous clinical outcomes and treatment intensity, which in turn affect product selection and service utilization. End users such as ambulatory surgical centers, hospitals, and specialty clinics differ in their capital budgets, case-mix, and referral networks, shaping procurement timelines and commercial engagement strategies. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies influence patient access, adherence support, and channel economics. Taken together, these segmentations underline that tailoring clinical evidence, pricing models, and post-market services to the specific combination of product, therapy, tumor type, and care setting is essential to accelerate adoption and create defensible commercial positioning.

Unpacking regional regulatory and payer heterogeneity to tailor evidence generation, market entry sequencing, and local commercialization tactics for global reach

Regional dynamics create distinct regulatory, reimbursement, and clinical adoption environments that require localized go-to-market strategies. In the Americas, advanced academic centers and integrated health systems often drive early adoption of high-cost therapeutics and complex devices, while private payers and bundled payment models shape access and reimbursement pathways. Europe, the Middle East & Africa encompasses regulatory heterogeneity and varying reimbursement thresholds, where centralized approvals coexist with decentralized health technology assessments, necessitating flexible evidence dossiers and region-specific economic models. Asia-Pacific presents diverse healthcare modernization trajectories; in some markets rapid hospital expansion and investment in oncology centers create significant demand for high-capability devices and novel therapeutics, whereas other markets emphasize cost containment and local manufacturing partnerships.

These regional contrasts affect clinical trial site selection, timing of market entry, and the design of patient access programs. Manufacturers must therefore calibrate regulatory strategies, local evidence generation, and distribution partnerships to align with regional payer expectations and provider capabilities. Moreover, engagement with key opinion leaders and local clinical networks is essential to translate global evidence into locally relevant practice change and to expedite reimbursement discussions in each jurisdiction.

How integrated product and service strategies among innovators, device makers, and distributors are redefining competitive advantage and partnership models

Key companies in the brain tumor therapeutics ecosystem operate across complementary domains-innovative drug developers, device manufacturers, service providers, and specialized distributors-each contributing to a complex value chain. Pharmaceutical innovators are increasingly pairing molecularly targeted agents and immunotherapies with companion diagnostics, elevating the role of biomarker-driven patient selection in clinical and commercial success. Device manufacturers are differentiating through integrated solutions that combine imaging, navigation, and therapeutic delivery to streamline operative workflows and improve clinical outcomes.

Service providers and contract research organizations are expanding offerings to support adaptive trial designs, real-world evidence platforms, and health economic modeling, enabling sponsors to substantiate value propositions more rapidly. Distributors and specialty pharmacies are enhancing patient support programs and specialty logistics to address the needs of high-acuity populations. Across the ecosystem, strategic collaborations-whether co-development, licensing, or integrated service agreements-have become a preferred vehicle to de-risk innovation and accelerate time-to-clinic or time-to-market. Organizations that can demonstrate integrated solutions, scalable support models, and strong clinical evidence will lead in both clinical adoption and long-term commercial sustainability.

Prioritized strategic moves for executives to synchronize evidence generation, supply resilience, and flexible commercialization to accelerate adoption

Industry leaders should prioritize a set of actionable initiatives that align scientific differentiation with pragmatic commercial execution and payer expectations. First, invest in targeted evidence generation that pairs clinical endpoints with health economic outcomes, enabling payers and health systems to assess long-term value alongside short-term efficacy. Second, optimize supply chain resilience by diversifying sourcing, building redundancy for critical components, and embedding tariff and trade sensitivity analyses into pricing models to protect margins and continuity of care. Third, develop flexible commercial models that reflect end-user variability; hospitals, ambulatory surgical centers, and specialty clinics require different acquisition, financing, and service arrangements.

Additionally, engage early with regional regulatory and reimbursement stakeholders to ensure local evidence requirements are met, and consider adaptive trial designs or pragmatic studies to accelerate real-world adoption. Form strategic alliances that integrate devices and therapeutics with digital tools and patient support services to create bundled value propositions. Finally, prioritize clinician and patient education programs that clarify treatment sequencing, combination therapy rationale, and outcome expectations, thereby smoothing the pathway from regulatory approval to standard-of-care integration. Collectively, these actions will reduce barriers to adoption and enhance commercial resilience.

A transparent mixed-methods approach combining clinical, commercial, and policy intelligence with expert interviews and comparative case analyses to ensure actionable insights

The research methodology underpinning this analysis combines systematic literature review, primary qualitative interviews with subject matter experts, and triangulation of secondary data sources to ensure robustness and relevance. Primary interviews included clinicians, hospital procurement leaders, device engineers, payers, and commercial executives to capture cross-functional perspectives on clinical utility, procurement preferences, and market access contingencies. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, guideline updates, and public policy announcements to ground the findings in verifiable evidence and current practice patterns.

Data synthesis employed thematic analysis to identify recurring adoption drivers, barriers, and regional variances, while comparative case studies highlighted successful commercialization and partnership archetypes. Where appropriate, sensitivity checks were performed to validate assumptions around supply chain dynamics and provider purchasing behaviors. The methodology emphasizes transparency in source attribution and analytical assumptions and was designed to produce actionable insights that are reliable for strategic planning, partnership evaluation, and evidence generation prioritization.

Synthesizing clinical innovation, commercial rigor, and regional nuance to identify the strategic levers that convert therapeutic advances into durable impact

In conclusion, the brain tumor therapeutics arena is characterized by rapid scientific progress, evolving care pathways, and complex commercial dynamics that together demand integrated strategies across evidence generation, supply chain design, and market access. Precision diagnostics and novel immunotherapies have raised the bar for clinical differentiation, while advances in imaging, radiation delivery, and surgical technique are reshaping practice patterns. At the same time, tariff and trade shifts have exposed supply chain vulnerabilities that require proactive management to preserve access and fiscal performance. Regional heterogeneity in regulation and reimbursement further underscores the need for localized strategies and partnerships.

Taken together, organizations that can align robust clinical evidence with pragmatic commercial models, resilient procurement practices, and targeted regional engagement will be best positioned to convert innovation into sustained clinical and commercial impact. The path forward emphasizes collaboration across industry, clinical, and payer stakeholders, and a disciplined approach to evidence and value demonstration that meets the needs of providers and patients alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increased adoption of personalized vaccine therapies targeting tumor-specific antigens
• 5.2. Emergence of multi-modal treatment regimens combining immunotherapy and targeted agents
• 5.3. Advancements in blood-based liquid biopsy assays for early detection of brain tumor recurrence
• 5.4. Rising investment in CAR T-cell therapies for aggressive and recurrent glioblastoma cases
• 5.5. Integration of AI-powered imaging analytics to improve tumor segmentation and treatment planning
• 5.6. Development of blood-brain barrier penetrating small molecules for diffuse intrinsic pontine glioma
• 5.7. Growing emphasis on patient-reported outcomes to guide neurocognitive sparing treatment strategies
• 5.8. Strategic collaborations between biotech pioneers and academic centers for novel glioma target discovery
• 5.9. Regulatory approvals accelerating availability of oncolytic virus therapies for high-grade gliomas
• 5.10. Investment in adaptive clinical trial designs to accelerate brain tumor therapeutic evaluations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Therapeutics Market, by Product Type

• 8.1. Devices
  • 8.1.1. Imaging Equipment
  • 8.1.2. Radiation Equipment
  • 8.1.3. Surgical Instruments
• 8.2. Pharmaceutical

9. Brain Tumor Therapeutics Market, by Therapeutic Approach

• 9.1. Chemotherapy
  • 9.1.1. Alkylating Agents
  • 9.1.2. Antimetabolites
  • 9.1.3. Plant Alkaloids
• 9.2. Immunotherapy
  • 9.2.1. CAR T
  • 9.2.2. Checkpoint Inhibitors
  • 9.2.3. Vaccines
• 9.3. Radiotherapy
  • 9.3.1. Brachytherapy
  • 9.3.2. External Beam Radiotherapy
  • 9.3.3. Stereotactic Radiosurgery
• 9.4. Surgery
  • 9.4.1. Craniotomy
  • 9.4.2. Stereotactic Surgery

10. Brain Tumor Therapeutics Market, by Tumor Type

• 10.1. Astrocytoma
• 10.2. Glioblastoma
• 10.3. Meningioma

11. Brain Tumor Therapeutics Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Brain Tumor Therapeutics Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Online Pharmacies
• 12.3. Retail Pharmacies

13. Brain Tumor Therapeutics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Brain Tumor Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Brain Tumor Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Merck & Co., Inc.
  • 16.3.2. F. Hoffmann-La Roche Ltd.
  • 16.3.3. Novocure Ltd.
  • 16.3.4. Bristol-Myers Squibb Company
  • 16.3.5. Pfizer Inc.
  • 16.3.6. AbbVie Inc.
  • 16.3.7. AstraZeneca plc
  • 16.3.8. Novartis AG
  • 16.3.9. Teva Pharmaceutical Industries Ltd.
  • 16.3.10. GlaxoSmithKline plc

LIST OF FIGURES

• FIGURE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018